Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus

References

• Gorwitz RJ, Kruszon-Moran D, McAllister SK, McQuillan G, McDougal LK, Fosheim GE, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197:1226 - 34; http://dx.doi.org/10.1086/533494; PMID: 18422434
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, et al, EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54:1126 - 33; http://dx.doi.org/10.1093/cid/cis022; PMID: 22438343
   PubMed Web of Science ®Google Scholar
• Nimmo GR. USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2012; 18:725 - 34; http://dx.doi.org/10.1111/j.1469-0691.2012.03822.x; PMID: 22448902
   PubMed Web of Science ®Google Scholar
• Tong SY, Chen LF, Fowler VG Jr.. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?. Semin Immunopathol 2012; 34:185 - 200; http://dx.doi.org/10.1007/s00281-011-0300-x; PMID: 22160374
   PubMed Web of Science ®Google Scholar
• Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183 - 9; PMID: 9784520
   PubMed Web of Science ®Google Scholar
• Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, et al. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 2011; 7:Suppl 51 - 9; http://dx.doi.org/10.4161/hv.7.0.14562; PMID: 21245656
   PubMed Web of Science ®Google Scholar
• Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023 - 32; PMID: 8432585
   PubMed Web of Science ®Google Scholar
• Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659 - 65; PMID: 8613375
   PubMed Web of Science ®Google Scholar
• Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146 - 51; PMID: 9317020
   PubMed Web of Science ®Google Scholar
• Peterson PK, Verhoef J, Sabath LD, Quie PG. Effect of protein A on staphylococcal opsonization. Infect Immun 1977; 15:760 - 4; PMID: 870431
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165 - 9; http://dx.doi.org/10.1128/CVI.13.2.165-169.2006; PMID: 16467321
   PubMed Web of Science ®Google Scholar
• Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 2009; 27:3276 - 80; http://dx.doi.org/10.1016/j.vaccine.2009.01.062; PMID: 19200819
   PubMed Web of Science ®Google Scholar
• Dassy B, Stringfellow WT, Lieb M, Fournier JM. Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semi-synthetic medium. J Gen Microbiol 1991; 137:1155 - 62; http://dx.doi.org/10.1099/00221287-137-5-1155; PMID: 1865184
   PubMedGoogle Scholar
• Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002; 30:315 - 22; http://dx.doi.org/10.1097/00003246-200202000-00009; PMID: 11889301
   PubMed Web of Science ®Google Scholar
• Verbrugh HA, Peterson PK, Nguyen BY, Sisson SP, Kim Y. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol 1982; 129:1681 - 7; PMID: 7108223
   PubMed Web of Science ®Google Scholar
• Verdrengh M, Tarkowski A. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun 1997; 65:2517 - 21; PMID: 9199413
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328 - 40; PMID: 5216294
   PubMed Web of Science ®Google Scholar
• Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol Biol 2007; 412:489 - 504; http://dx.doi.org/10.1007/978-1-59745-467-4_30; PMID: 18453130
   PubMedGoogle Scholar
• Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15:578 - 84; http://dx.doi.org/10.1016/S0952-7915(03)00109-2; PMID: 14499268
   PubMed Web of Science ®Google Scholar
• Johnston RB Jr., Keele BB Jr., Misra HP, Lehmeyer JE, Webb LS, Baehner RL, et al. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest 1975; 55:1357 - 72; http://dx.doi.org/10.1172/JCI108055; PMID: 166094
   PubMed Web of Science ®Google Scholar
• Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 1967; 46:668 - 79; http://dx.doi.org/10.1172/JCI105568; PMID: 6021213
   PubMed Web of Science ®Google Scholar
• Cunnion KM, Benjamin DK Jr., Hester CG, Frank MM. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med 2004; 143:358 - 65; http://dx.doi.org/10.1016/j.lab.2004.03.005; PMID: 15192652
   PubMedGoogle Scholar
• Cunnion KM, Lee JC, Frank MM. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun 2001; 69:6796 - 803; http://dx.doi.org/10.1128/IAI.69.11.6796-6803.2001; PMID: 11598052
   PubMed Web of Science ®Google Scholar
• Cunnion KM, Zhang HM, Frank MM. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun 2003; 71:656 - 62; http://dx.doi.org/10.1128/IAI.71.2.656-662.2003; PMID: 12540542
   PubMed Web of Science ®Google Scholar
• Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359 - 95; PMID: 1889047
   PubMed Web of Science ®Google Scholar
• Mickenberg ID, Root RK, Wolff SM. Leukocytic function in hypogammaglobulinemia. J Clin Invest 1970; 49:1528 - 38; http://dx.doi.org/10.1172/JCI106370; PMID: 4194088
   PubMed Web of Science ®Google Scholar
• Xu S, Arbeit RD, Lee JC. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1992; 60:1358 - 62; PMID: 1548061
   PubMed Web of Science ®Google Scholar
• Mishra RP, Mariotti P, Fiaschi L, Nosari S, Maccari S, Liberatori S, et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis 2012; 206:1041 - 9; http://dx.doi.org/10.1093/infdis/jis463; PMID: 22829645
   PubMed Web of Science ®Google Scholar
• Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother 2012; 8:8; PMID: 22922765
   PubMed Web of Science ®Google Scholar
• Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560 - 7; http://dx.doi.org/10.1093/cid/cir828; PMID: 22186773
   PubMed Web of Science ®Google Scholar
• Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012; 15:92 - 9; http://dx.doi.org/10.1016/j.mib.2011.10.012; PMID: 22088393
   PubMed Web of Science ®Google Scholar
• Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis 2012; 55:1188 - 97; http://dx.doi.org/10.1093/cid/cis624; PMID: 22806596
   PubMed Web of Science ®Google Scholar
• Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 2012; 19:1641 - 50; http://dx.doi.org/10.1128/CVI.00354-12; PMID: 22896688
   PubMed Web of Science ®Google Scholar